Izbicka Maria, Gasińska Teresa, Dec Renata
Wojewódzka Poradnia Endokrynologiczna w Katowicach.
Wiad Lek. 2010;63(1):10-6.
Cardiovascular abnormalities may be the only manifestations of overt hyperthyroidism. In patients with heart failure and atrial fibrillation digoxin can be beneficial in controlling the symptoms and signs, but hyperthyroid patients show an impaired response or even resistance to digoxin treatment. The aim of the study is to establish: 1. Are there any differences in the pharmacokinetics of a single oral dose of digoxin between hypertyroid and euthyroid patients? 2. Does simultaneous administration of digoxin and methimazole affect the pharmacokinetics of a single oral dose of dogoxin? 3. Does methimazole-induced euthyroidism change the pharmacokinetics of a single oral dose of digoxin?
The subject of the study were 28 patients with hyperthyroidism and 15 healthy persons. We evaluated the pharmacokinetics of a single oral dose of digoxin. Moreover we evaluated pharmacokinetics of a single dose of digoxin after simultaneous administration of digoxin and methimazole in 12 patients and 12 methimazole treated patients werere-assessed once they had become euthyroid.
Hyperthyroid patients showed significantly lower serum digoxin concentrations, shorter T1/2 beta and a significantly smaller area under the concentration curve (AUC) that the control group. Administration of methimazole did not affect digoxin pharmacokinetics.
In hyperthyroid patients: 1. the pharmacokinetics of a single oral dose of digoxin does differ from that observed in healthy subjects. 2.methimazole do not alter digoxin pharmacokinetics.
心血管异常可能是显性甲状腺功能亢进的唯一表现。在心力衰竭和心房颤动患者中，地高辛有助于控制症状和体征，但甲状腺功能亢进患者对地高辛治疗的反应受损甚至产生耐药性。本研究的目的是确定：1. 甲状腺功能亢进患者和甲状腺功能正常患者单次口服地高辛的药代动力学是否存在差异？2. 同时给予地高辛和甲巯咪唑是否会影响单次口服地高辛的药代动力学？3. 甲巯咪唑诱导的甲状腺功能正常是否会改变单次口服地高辛的药代动力学？
本研究的对象为28例甲状腺功能亢进患者和15名健康人。我们评估了单次口服地高辛的药代动力学。此外，我们评估了12例患者同时给予地高辛和甲巯咪唑后单次剂量地高辛的药代动力学，并在12例接受甲巯咪唑治疗的患者甲状腺功能恢复正常后重新进行评估。
甲状腺功能亢进患者的血清地高辛浓度显著低于对照组，T1/2β更短，浓度曲线下面积（AUC）显著更小。给予甲巯咪唑不影响地高辛的药代动力学。
在甲状腺功能亢进患者中：1. 单次口服地高辛的药代动力学与健康受试者观察到的不同。2. 甲巯咪唑不会改变地高辛的药代动力学。
